Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)
Bangladesh · Delayed Price · Currency is BDT 113.00
-1.70 (-1.48%)
At close: Oct 30, 2025
Beacon Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| 11,579 | 10,702 | 8,510 | 8,023 | 7,121 | 5,591 | Upgrade | |
Revenue Growth (YoY) | 23.15% | 25.75% | 6.07% | 12.66% | 27.37% | 20.31% | Upgrade |
Cost of Revenue | 5,609 | 5,215 | 4,251 | 3,906 | 3,452 | 2,724 | Upgrade |
Gross Profit | 5,970 | 5,487 | 4,259 | 4,116 | 3,669 | 2,867 | Upgrade |
Selling, General & Admin | 3,793 | 3,672 | 3,295 | 2,499 | 2,307 | 2,533 | Upgrade |
Other Operating Expenses | -13.85 | -13.85 | -14.86 | - | - | - | Upgrade |
Operating Expenses | 3,779 | 3,659 | 3,280 | 2,499 | 2,307 | 2,533 | Upgrade |
Operating Income | 2,191 | 1,828 | 979.12 | 1,617 | 1,362 | 333.47 | Upgrade |
Interest Expense | -1,284 | -1,003 | -460.92 | -337.96 | -164.82 | -149.33 | Upgrade |
Interest & Investment Income | 227.86 | 227.86 | 155.13 | 0.32 | 3.24 | 1.31 | Upgrade |
Currency Exchange Gain (Loss) | -93.69 | -93.69 | 2.68 | 0.5 | - | - | Upgrade |
Other Non Operating Income (Expenses) | 59.94 | - | - | 9.81 | -1.98 | -0.95 | Upgrade |
EBT Excluding Unusual Items | 1,102 | 959.82 | 676.01 | 1,290 | 1,198 | 184.5 | Upgrade |
Gain (Loss) on Sale of Assets | -6.5 | -6.5 | 3.07 | 3.04 | - | - | Upgrade |
Pretax Income | 1,095 | 953.32 | 679.07 | 1,293 | 1,198 | 184.5 | Upgrade |
Income Tax Expense | 524.99 | 432.31 | 169.23 | 357.93 | 334.99 | -196.19 | Upgrade |
Net Income | 570.05 | 521.01 | 509.84 | 935.04 | 863.17 | 380.69 | Upgrade |
Net Income to Common | 570.05 | 521.01 | 509.84 | 935.04 | 863.17 | 380.69 | Upgrade |
Net Income Growth | -13.90% | 2.19% | -45.47% | 8.33% | 126.74% | 223.44% | Upgrade |
Shares Outstanding (Basic) | 231 | 231 | 231 | 231 | 231 | 231 | Upgrade |
Shares Outstanding (Diluted) | 231 | 231 | 231 | 231 | 231 | 231 | Upgrade |
EPS (Basic) | 2.47 | 2.26 | 2.21 | 4.05 | 3.74 | 1.65 | Upgrade |
EPS (Diluted) | 2.47 | 2.26 | 2.21 | 4.05 | 3.74 | 1.65 | Upgrade |
EPS Growth | -13.90% | 2.19% | -45.47% | 8.33% | 126.74% | 223.44% | Upgrade |
Free Cash Flow | 1,516 | -1,275 | -1,193 | -637.07 | -116.85 | -22.8 | Upgrade |
Free Cash Flow Per Share | 6.56 | -5.52 | -5.17 | -2.76 | -0.51 | -0.10 | Upgrade |
Dividend Per Share | 2.000 | 2.000 | 1.600 | 1.600 | 1.500 | - | Upgrade |
Dividend Growth | 25.00% | 25.00% | - | 6.67% | - | - | Upgrade |
Gross Margin | 51.56% | 51.27% | 50.05% | 51.31% | 51.52% | 51.28% | Upgrade |
Operating Margin | 18.92% | 17.09% | 11.51% | 20.16% | 19.12% | 5.96% | Upgrade |
Profit Margin | 4.92% | 4.87% | 5.99% | 11.65% | 12.12% | 6.81% | Upgrade |
Free Cash Flow Margin | 13.09% | -11.91% | -14.02% | -7.94% | -1.64% | -0.41% | Upgrade |
EBITDA | 2,723 | 2,356 | 1,498 | 2,057 | 1,747 | 844.48 | Upgrade |
EBITDA Margin | 23.52% | 22.02% | 17.60% | 25.64% | 24.53% | 15.10% | Upgrade |
D&A For EBITDA | 532.21 | 527.78 | 518.92 | 439.7 | 385.16 | 511.01 | Upgrade |
EBIT | 2,191 | 1,828 | 979.12 | 1,617 | 1,362 | 333.47 | Upgrade |
EBIT Margin | 18.92% | 17.09% | 11.51% | 20.16% | 19.12% | 5.96% | Upgrade |
Effective Tax Rate | 47.94% | 45.35% | 24.92% | 27.68% | 27.96% | - | Upgrade |
Advertising Expenses | - | 72.55 | 69.04 | 68.5 | 52.97 | 1,004 | Upgrade |
Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.